Group E of the phase I/II CheckMate 370 evaluated the safety of the combination of nivolumab (240 mg once every two weeks) and crizotinib (250 mg twice daily) as first-line treatment for previously untreated ALK-rearranged advanced NSCLC patients. Here, ALK is linked to non-small cell lung carcinoma.